MLYS - Company ID 0001933414
Mineralys Therapeutics, Inc. trades as MLYS and has a market capitalization of $2.40 B, making it the #2007 largest US-listed company by market value. This page tracks Mineralys Therapeutics, Inc. through 350 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Major company event | 8-K | 2026-05-22 |
| Insider trade | 4 | 2026-05-19 |
| Insider sale notice | 144 | 2026-05-18 |
| Insider sale notice | 144 | 2026-05-13 |
| Insider trade | 4 | 2026-05-13 |
| Insider sale notice | 144 | 2026-05-12 |
| Insider sale notice | 144 | 2026-05-11 |
| Quarterly report | 10-Q | 2026-05-06 |
Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026) :: Mineralys Therapeutics, Inc. (MLYS)
Mineralys Therapeutics to Participate in the Jefferies Global Healthcare Conference
Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026) :: Mineralys Therapeutics, Inc. (MLYS)
Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update :: Mineralys Therapeutics, Inc. (MLYS)
The largest companies sharing Mineralys Therapeutics, Inc.'s SEC industry classification (pharmaceutical preparations).
Mineralys Therapeutics, Inc. (MLYS) has a market capitalization of $2.40 B as of 2026-07-09, ranking #2007 among US-listed companies.
In its latest fiscal year Mineralys Therapeutics, Inc. reported a net loss of $154.65M.